Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 90 Records) |
Query Trace: Glioma and MGMT[original query] |
---|
Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype. Neurology 2020 12 96 (7): e1063-e1069. Diaz Maria, Jo Jasmin, Smolkin Mark, Ratcliffe Sarah Jane, Schiff Dav |
Karnofsky Performance Scale and Neurological Assessment of Neuro-Oncology Scale as Early Predictor in Glioma. Asian Pacific journal of cancer prevention : APJCP 2020 11 21 (11): 3387-3392. Gunawan Pricilla Yani, Islam Andi Asadul, July Julius, Patellongi Ilhamjaya, Nasrum Muhammad, Aninditha Tia |
Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II. Scientific reports 2020 11 10 (1): 19758. Karschnia Philipp, Teske Nico, Dorostkar Mario M, Siller Sebastian, Weller Jonathan, Baehring Joachim M, Dietrich Jorg, von Baumgarten Louisa, Herms Jochen, Tonn Joerg-Christian, Thon Nikl |
An insertion variant of MGMT disrupts a STAT1 binding site and confers susceptibility to glioma. Cancer cell international 2021 Sep 21 (1): 506. Huang Liming, Xu Wenshen, Yan Danfang, Shi Xi, You Xin, Xu Jiaqi, You Pingping, Ke Yuanyuan, Dai Li |
High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase. Radiation oncology (London, England) 2021 Aug 16 (1): 157. Liu Yanwei, Li Yanong, Wang Peng, Chen Li, Feng Jin, Qiu Xiaogua |
High prevalence of developmental venous anomaly in adult patients with midline thalamic diffuse gliomas. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021 4 87 59-65. Zhou Xingwang, Niu Xiaodong, Mao Qing, Liu Yanh |
Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging. Neuroradiology 2021 3 63 (11): 1811-1822. Park Yae Won, Ahn Sung Soo, Moon Ju Hyung, Kim Eui Hyun, Kang Seok-Gu, Chang Jong Hee, Kim Se Hoon, Lee Seung-K |
Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma. Future science OA 2021 2 7 (3): FSO663. Pandith Arshad A, Qasim Iqbal, Baba Shahid M, Koul Aabid, Zahoor Wani, Afroze Dil, Lateef Adil, Manzoor Usma, Bhat Ina A, Sanadhya Dheera, Bhat Abdul R, Ramzan Altaf U, Mohammad Fozia, Anwar Iq |
Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? European journal of cancer (Oxford, England : 1990) 2021 2 147 84-94. Gramatzki Dorothee, Felsberg Jörg, Hentschel Bettina, Wolter Marietta, Schackert Gabriele, Westphal Manfred, Regli Luca, Thon Niklas, Tatagiba Marcos, Wick Wolfgang, Schlegel Uwe, Krex Dietmar, Matschke Jakob, Roth Patrick, Suresh Marian P, Kamp Marcel A, Rushing Elisabeth J, Pietsch Torsten, von Deimling Andreas, Sabel Michael, Loeffler Markus, Weller Michael, Reifenberger Gui |
High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting? Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 2 23 (7): 1358-1367. Gupta T, Maitre M, Maitre P, Goda J S, Krishnatry R, Chatterjee A, Moiyadi A, Shetty P, Epari S, Sahay A, Patil V, Jalali |
A Hypoxia-Related Long Non-Coding RNAs Signature Associated With Prognosis in Lower-Grade Glioma. Frontiers in oncology 2021 11 771512. Feng Qinglin, Qian Cheng, Fan Shibi |
ADD3 Deletion in Glioblastoma Predicts Disease Status and Survival. Frontiers in oncology 2021 12 11 717793. Kiang Karrie Mei-Yee, Sun Stella, Leung Gilberto Ka-K |
Glioma Imaging by O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Diffusion-Weighted MRI and Correlation With Molecular Phenotypes, Validated by PET/MR-Guided Biopsies. Frontiers in oncology 2021 12 11 743655. Cheng Ye, Song Shuangshuang, Wei Yukui, Xu Geng, An Yang, Ma Jie, Yang Hongwei, Qi Zhigang, Xiao Xinru, Bai Jie, Xu Lixin, Hu Zeliang, Sun Tingting, Wang Leiming, Lu Jie, Lin Qingta |
Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas. Cancer management and research 2021 12 13 8755-8765. Yang Zixi, Ling Feng, Ruan Sibei, Hu Jiajia, Tang Mingxi, Sun Xingwang, Long Wen |
Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set. International journal of molecular sciences 2021 Nov 22 (22): . Zappe Katja, Pirker Christine, Miedl Heidi, Schreiber Martin, Heffeter Petra, Pfeiler Georg, Hacker Stefan, Haslik Werner, Spiegl-Kreinecker Sabine, Cichna-Markl Marg |
TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy. Cancers 2021 11 13 (21): . Noor Humaira, Briggs Nancy E, McDonald Kerrie L, Holst Jeff, Vittorio Oraz |
Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS neuroscience & therapeutics 2021 1 27 (4): 470-483. Yu Hai, Zhang Duanni, Lian Minx |
Integrative analysis of CBR1 as a prognostic factor associated with IDH-mutant glioblastoma in the Chinese population. American journal of translational research 2022 9 14 (8): 5394-5408. Ji Pengxiang, Shan Xueshi, Wang Jian, Zhang Ping, Cai Zh |
Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis. Frontiers in neurology 2022 8 13 888221. Xu Wenshen, Huang Liming, Xie Bingsen, Yang B |
Brain radiotoxicity-related 15CAcBRT gene expression signature predicts survival prognosis of glioblastoma patients. Neuro-oncology 2022 Jul . Reyes-González Jesús, Barajas-Olmos Francisco, García-Ortiz Humberto, Magraner-Pardo Lorena, Pons Tirso, Moreno Sergio, Aguirre-Cruz Lucinda, Reyes-Abrahantes Andy, Martínez-Hernández Angélica, Contreras-Cubas Cecilia, Barrios-Payan Jorge, Ruiz-Garcia Henry, Hernandez-Pando Rogelio, Quiñones-Hinojosa Alfredo, Orozco Lorena, Abrahantes-Pérez María Del Carm |
Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma. Journal of neuro-oncology 2022 7 159 (2): 397-408. Suzuki Hayato, Ono Takahiro, Koyota Souichi, Takahashi Masataka, Sugai Tamotsu, Nanjo Hiroshi, Shimizu Hiroa |
HLA-G 14bp Ins/Del Polymorphism, Plasma Level of Soluble HLA-G, and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Diagnostics (Basel, Switzerland) 2022 5 12 (5): . Bucova Maria, Kluckova Kristina, Kozak Jan, Rychly Boris, Suchankova Magda, Svajdler Marian, Matejcik Viktor, Steno Juraj, Zsemlye Eszter, Durmanova Vladimi |
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 3 28 (11): 2440-2448. Draaisma Kaspar, Tesileanu C Mircea S, de Heer Iris, Klein Martin, Smits Marion, Reijneveld Jaap C, Clement Paul M, de Vos Filip Y F, Wick Antje, Mulholland Paul J, Taphoorn Martin J B, Weller Michael, Chinot Olivier L, Kros Johan M, Verschuere Tina, Coens Corneel, Golfinopoulos Vassilis, Gorlia Thierry, Idbaih Ahmed, Robe Pierre A, van den Bent Martin J, French Pim |
Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma. Bosnian journal of basic medical sciences 2022 3 22 (5): 728-750. Wang Jie, Ren Jie, Liu Jifeng, Zhang Linyun, Yuan Qihang, Dong B |
Analytic approaches to clinical validation of results from preclinical models of glioblastoma: A systematic review. PloS one 2022 3 17 (3): e0264740. Fitt Beth, Loy Grace, Christopher Edward, Brennan Paul M, Poon Michael Tin Chu |
High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta neuropathologica 2022 2 143 (3): 403-414. Pratt Drew, Abdullaev Zied, Papanicolau-Sengos Antonios, Ketchum Courtney, Panneer Selvam Pavalan, Chung Hye-Jung, Lee Ina, Raffeld Mark, Gilbert Mark R, Armstrong Terri S, Pytel Peter, Borys Ewa, Klonoski Joshua M, McCord Matthew, Horbinski Craig, Brat Daniel, Perry Arie, Solomon David, Eberhart Charles, Giannini Caterina, Quezado Martha, Aldape Kenne |
The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. International journal of molecular sciences 2022 11 23 (21): . Jovanovi? Nikola, Lazarevi? Milica, Cvetkovi? Vladimir J, Nikolov Vesna, Kosti? Peri? Jelena, Ugrin Milena, Pavlovi? Sonja, Mitrovi? Tatja |
Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study. Journal of neuro-oncology 2022 1 156 (3): 625-634. Moitra Prithwijit, Chatterjee Abhishek, Kota Priti Khatri, Epari Sridhar, Patil Vijay, Dasgupta Archya, Kowtal Pradnya, Sarin Rajiv, Gupta Tejp |
The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma. Frontiers in immunology 2022 13 998236. Wang Weichen, Lu Zhichao, Wang Maoyu, Liu Zongheng, Wu Bing, Yang Chengkai, Huan He, Gong Peip |
RYK Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients. Pharmaceuticals (Basel, Switzerland) 2023 5 16 (5): . Ricardo D Gonzalez, George W Small, Adrian J Green, Farida S Akhtari, Tammy M Havener, Julia C F Quintanilha, Amber B Cipriani, David M Reif, Howard L McLeod, Alison A Motsinger-Reif, Tim Wiltshi |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: